Predictors of unstable anticoagulation in African Americans

被引:20
作者
Cavallari, Larisa H. [1 ]
Aston, Jonathan L. [1 ]
Momary, Kathryn M. [1 ]
Shapiro, Nancy L. [1 ]
Patel, Shitalben R. [1 ]
Nutescu, Edith A. [1 ]
机构
[1] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL 60612 USA
关键词
Warfarin; African American; International normalized ratio; Genotype; ORAL ANTICOAGULATION; WARFARIN; VKORC1; CYP2C9; OUTCOMES; POLYMORPHISMS; MANAGEMENT; STABILITY; PROGRAM; CARE;
D O I
10.1007/s11239-008-0236-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective We sought to identify contributors to unstable anticoagulation in African Americans. Patients and methods Sixty African Americans on warfarin were enrolled. Cytochrome P450 2C9 and vitamin K epoxide reductase genotypes and vitamin K intake were assessed, and clinical and dietary data during the 12 months prior to enrollment were collected. Data were compared between stable and unstable patients, classified based on the proportion of international normalized ratio (INR) values outside the therapeutic range. Results The median proportion of out-of-range INRs among study participants was 44%; 28 patients had a higher proportion of INRs out-of-range and were included in the unstable group, with the remaining constituting the stable group. The median (IQR) number of clinic visits/year was higher among unstable versus stable patients [18 (15-22) vs. 16 (13-19); P = 0.03]. Higher warfarin doses, lower adherence, vomiting or diarrhea, and use of antiinfective agents were more common among unstable patients. Genotype was not associated with anticoagulation stability. After regression analysis, only poor adherence and gastrointestinal illness remained predictive of unstable anticoagulation. In a control group of Caucasians of similar age and sex distribution, poor adherence, but not gastrointestinal illness, was associated with unstable anticoagulation. Conclusion We conclude that poor warfarin adherence and gastrointestinal illness are major contributors to unstable anticoagulation in African Americans. Our data suggest that, similar to Caucasians, improving warfarin adherence rates may be an important mean to improve anticoagulation control in African Americans. In addition, close monitoring during acute illness may be particularly important in this population.
引用
收藏
页码:430 / 437
页数:8
相关论文
共 28 条
  • [1] Abdelhafiz Ahmed H, 2003, Am J Geriatr Pharmacother, V1, P53, DOI 10.1016/S1543-5946(03)90001-8
  • [2] Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
    Anderson, Jeffrey L.
    Horne, Benjamin D.
    Stevens, Scott M.
    Grove, Amanda S.
    Barton, Stephanie
    Nicholas, Zachery P.
    Kahn, Samera F. S.
    May, Heidi T.
    Samuelson, Kent M.
    Muhlestein, Joseph B.
    Carlquist, John F.
    [J]. CIRCULATION, 2007, 116 (22) : 2563 - 2570
  • [3] Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies
    Andrisin, TE
    Humma, LM
    Johnson, JA
    [J]. PHARMACOTHERAPY, 2002, 22 (08): : 954 - 960
  • [4] The pharmacology and management of the vitamin K antagonists
    Ansell, J
    Hirsh, J
    Poller, L
    Bussey, H
    Jacobson, A
    Hylek, E
    [J]. CHEST, 2004, 126 (03) : 204S - 233S
  • [5] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
    Aquilante, CL
    Langaee, TY
    Lopez, LM
    Yarandi, HN
    Tromberg, JS
    Mohuczy, D
    Gaston, KL
    Waddell, CD
    Chirico, MJ
    Johnson, JA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
  • [6] Comparison of an anticoagulation clinic with usual medical care -: Anticoagulation control, patient outcomes, and health care costs
    Chiquette, E
    Amato, MG
    Bussey, HI
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (15) : 1641 - 1647
  • [7] Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
    Gage, BF
    Eby, C
    Milligan, PE
    Banet, GA
    Duncan, JR
    McLeod, HL
    [J]. THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) : 87 - 94
  • [8] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
    Higashi, MK
    Veenstra, DL
    Kondo, LML
    Wittkowsky, AK
    Srinouanprachanh, SL
    Farin, FM
    Rettie, AE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698
  • [9] Systematic overview of warfarin and its drug and food interactions
    Holbrook, AM
    Pereira, JA
    Labiris, R
    McDonald, H
    Douketis, JD
    Crowther, M
    Wells, PS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1095 - 1106
  • [10] Pyrosequencing method for genotyping cytochrome P450CYP2C8 and CYP2C9 enzymes
    Hruska, MW
    Frye, RF
    Langaee, TY
    [J]. CLINICAL CHEMISTRY, 2004, 50 (12) : 2392 - 2395